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Abstract 
The use of vaccines in poultry to control avian influenza viruses, especially mildly pathogenic avian influenza viruses has been 
increasing in recent years. In order to recommend any of the vaccines, it is important to evaluate the quality of them with an 
appropriate and rapid method. Three oil-emulsion vaccines commercially available against avian influenza viruses in Iran were 
evaluated for their quality by in-vitro assays. Total antigen was recovered from each vaccine by a method called aqueous partition. 
To normalize the immune response to the amount of the total protein available in each dose of each vaccine, the amount of extracted 
total protein and the amount of recovered hemagglutination activity were determined. Results showed that the amount of recovered 
total protein and activity of the recovered HA, were different in the vaccines tested. This difference was recorded for each dose of 
the vaccine used in the study. Also we showed that the hemagglutination inhibition activity of the antisera were different. It seems 
that the main reason for the low quality of the two vaccines compared to the other one is the low density of viral proteins in each 
dose of them. 
© 2010 Published by Elsevier Ltd.
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1. Introduction 
Influenza is a highly contagious viral disease which infects birds, humans and other mammalians. The agent of 
disease belongs to the family Orthomyxoviridae which was isolated and identified in 1933 (6,9). Influenza virus type A 
has been isolated from wild and domesticated birds throughout the world (3). Three subtypes of Avian Influenza 
Viruses (AIVs), H5N1, H7N7, and H9N2 have directly infected humans (6,12). H9N2 subtype which is a mildly 
pathogenic virus spread worldwide in 1994-1999 (1); Evolution of H9N2 subtype (10), its genetic relation with H5N1 
subtype (5), and its isolation from human, together (7,13), confirmed that the control of H9N2 viruses in poultry is 
important.  
The use of oil-emulsion (OE) vaccines to prevention and control of avian influenza (AI) was rapidly increased after 
studies between1969-1978. These vaccines stimulate humoral immunity in the host and protect it against the challenge 
with acute viruses such as viscerotropic velogenic Newcastle disease and highly pathogenic avian influenza (HPAI) 
viruses (16). Vaccination of poultry with OE vaccines against AIVs especially mildly pathogenic viruses (MPVs) has 
been increasing in recent years. 
The amount of viral proteins especially density and activity of hemagglutinin (HA) protein in AI OE-vaccines has 
the main role in immunogenicity and efficacy of the vaccines (4,16,17). With extraction of antigen mass of an AI OE-
vaccine and determination of recovered HA activity and the amount of extracted total protein, it is possible to predict 
the quality and protective efficacy of the vaccine instead of using vaccination and challenge trials which is a time-
consuming and expensive method, concerning ethical issues as well. 
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In this study antigen mass and the total protein of some AI OE-vaccines were extracted and the activity of recovered 
HA and the amount of total protein determined and compared with the serologic responses caused in chickens by each 
vaccine. 
2. Vaccines 
Three commercially available inactivated AI subtype H9N2 oil-emulsion vaccines (A, B, and C) used for this study. 
3. Extraction of the antigen mass by aqueous partition method 
To separate and measure aqueous phase of the OE-vaccines, 5 ml of each vaccine mixed with 3 ml of N-hexanol and 
centrifuged for15 min at 1000 g, 4 ˸C. For the extraction of the antigen mass from the intact vaccines, 12 doses of each 
vaccine (2.4 ml of vaccine A, 3.6 ml of vaccine B, and 3 ml of vaccine C) were added to centrifuge tubes containing 
phosphate-buffered saline (PBS), 1.33 ml, 2.63 ml, and 3ml respectively. Then, placed in an ice bath, and cooled to 0 ˸C 
(the ratio between PBS volume and aqueous phase volume was equal in the three vaccines). The contents were mixed 
using a Homogenizer (IKA ULTRA-TURRAX® T 18 basic) at 20000 rpm for 50 seconds on ice. The mixtures were 
then centrifuged at 1000 g for 15 min at 4C˸ to separate PBS fraction from the oil fraction of the OE-vaccine. HA 
activity of PBS fraction for each vaccine was determined and expressed as HA titer. Extraction of antigen mass was 
conducted 2 days before vaccination.  
4. Quantification of extracted protein 
Protein concentration of PBS fraction of the vaccines was determined by the method of Lowry et al (1951) using 
crystalline bovine serum (11). First 25 ml of 2% sodium carbonate was mixed with 25 ml of 0.1% sodium hydroxide 
solution to prepare Solution A. Then, 5 ml of Copper sulfate solution was mixed with 5 ml of 1% sodium potassium 
tartarate solution to prepare Solution B. 50 ml of solution A was mixed with 1 ml of solution B to prepare solution C. 
To quantify total protein, 0.2 ml extracted PBS from each vaccine was mixed with 1 ml Solution C and was incubated 
for 10 min at room temperature. 0.1 ml of Folin - Ciocalteau reagent solution (1N) was added to the test tubes and was 
vortexed briefly. After 30 min incubation, the absorbance of it determined at the wave length 550 nm. Standard curve 
prepared in the concentrations of 25, 50,100,200 and 400 ȝg/ml.  
5. Vaccine efficacy study 
One hundred day-old broiler chickens were obtained from a commercial hatchery and reared by standard practices. 
Before vaccination they were randomly divided equally into four groups (I, II, III, and IV) and placed in separate cages 
(25 chickens per each group) in an isolation room. The group I, II, and III received vaccine A (0.2 ml/ dose), vaccine B 
(0.3 ml/dose), and Vaccine C (0.25 ml/dose) respectively in the dorsal cervical region via the subcutaneous route at 11 
days of age. The group IV received PBS (0.3 ml) as control. Blood samples were taken at five weeks post-vaccination 
for haemagglutination inhibition (HI) test. HI titers expressed as HI mean titers based on 25 chickens per group.   
6. HI assay method 
Sera were tested for HI antibodies to avian influenza H9N2 using 4 HA units of the antigen as described by Beard & 
Wilkes (1973) (2). 
7. Statistical analysis 
Data were analyzed by spss package (16.2.2) using (Npar tests) Kruskal-Wallis test. 
8. Results and Discussion  
The results from this study showed that the aqueous partition method retrieves antigen mass from the inactivated AI 
subgroup H9N2 OE-vaccines, and also indicated that in three examined vaccines there is a good correlation among 
recovered hemagglutination activity, extracted total protein, and antibody response in each vaccine (Table 1). 
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Table 1. Correlation among recovered haemagglutination 
titers, extracted total protein, and HI titers. 
Vaccinesa HA titersc Total proteind 
(ȝg/ml) 
HI mte at 5-
wk post-
vaccination 
A 2 4.8 5.08 
B 0 2 2.76 
C 7 7 6.24 
Db - - 0.6 
                                                                       aInactivated avian Influenza H9N2 oil-emulsion vaccines. 
                                                                        bPBS as a negative control of vaccines. 
                                                                       c  Recovered haemagglutination titer. 
                                                                       dExtracted vaccine total protein. 
                                                                      e  Haemagglutination-inhibition  mean titers based on a total 
                                             of 25 chickens/group.  
 
 
Incomplete control of MPAI viruses and circulation of viruses in poultry houses may predispose antigen changes 
and possibly increase pathogenicity (8). Most commercial AI OE-vaccines only reduce or inhibit clinical signs and or 
mortality and do not prevent viral replication and shedding of AIVs completely (7). 
Numerous studies have indicated that the efficacy and immunogenicity of AI OE-vaccines depend on the amount of 
antigen mass especially HA protein (16,17). Garcia and others have shown that to prevent AI clinical signs a dose of 
vaccine must have approximately 0.4 ȝg hemagglutinin (4). Other study have shown that in order to induce immunity 
and prohibit viral shedding, the amount of hemagglutinin must be 0.5 ȝg (16).  
Stone has shown that by using aqueous partition method, it is possible to recover HA protein and determine HA 
activity from OE Newcastle disease vaccines (14).  
Both hemagglutinin and neuraminidase (NA), especially hemagglutinin, induce protective antibodies; in addition, 
there are some reports that indicate internal proteins mainly nucleoprotein (NP) of AI viruses induce antibodies which 
decrease titers of influenza replication in lungs (15), there is also a direct relationship between quantity of the whole 
virus and the hemagglutinin in a vaccine. It is also clear that in the PBS fraction of the vaccines, there are some 
recovered internal proteins including, NA, and matrix (M), besides hemagglutinin antigen. Therefore, it is possible to 
evaluate the quality of a vaccine by determining the extracted total protein instead of using vaccination and challenge 
trials. Therefore, by extracting and determining of total protein in a vaccine, one could acquire information about the 
potency of the vaccine. The results from this study showed that the aqueous partition method retrieves antigen mass 
from the AI subgroup H9N2 OE-vaccines, and also indicated that immune responses to the three examined vaccines are 
significantly different (P=0.000) at the same doses and the amount of extracted total protein and activity of the 
recovered HA are higher in vaccine C than the two others (vaccine A and B), (table 1). Based on the results of viral 
protein extraction and the activity of recovered HA, it seems that the main reason of low efficacy for the two vaccines 
is the low density of the viral proteins in vaccines. 
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